1. Home
  2. IPHA vs MPA Comparison

IPHA vs MPA Comparison

Compare IPHA & MPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPHA
  • MPA
  • Stock Information
  • Founded
  • IPHA 1999
  • MPA 1992
  • Country
  • IPHA France
  • MPA United States
  • Employees
  • IPHA N/A
  • MPA N/A
  • Industry
  • IPHA Biotechnology: Pharmaceutical Preparations
  • MPA Finance Companies
  • Sector
  • IPHA Health Care
  • MPA Finance
  • Exchange
  • IPHA Nasdaq
  • MPA Nasdaq
  • Market Cap
  • IPHA 160.1M
  • MPA 136.5M
  • IPO Year
  • IPHA 2019
  • MPA N/A
  • Fundamental
  • Price
  • IPHA $1.97
  • MPA $10.74
  • Analyst Decision
  • IPHA Strong Buy
  • MPA
  • Analyst Count
  • IPHA 1
  • MPA 0
  • Target Price
  • IPHA $11.50
  • MPA N/A
  • AVG Volume (30 Days)
  • IPHA 28.5K
  • MPA 25.2K
  • Earning Date
  • IPHA 03-27-2025
  • MPA 01-01-0001
  • Dividend Yield
  • IPHA N/A
  • MPA 3.83%
  • EPS Growth
  • IPHA N/A
  • MPA N/A
  • EPS
  • IPHA N/A
  • MPA N/A
  • Revenue
  • IPHA $20,831,349.00
  • MPA N/A
  • Revenue This Year
  • IPHA $220.44
  • MPA N/A
  • Revenue Next Year
  • IPHA $81.85
  • MPA N/A
  • P/E Ratio
  • IPHA N/A
  • MPA N/A
  • Revenue Growth
  • IPHA N/A
  • MPA N/A
  • 52 Week Low
  • IPHA $1.29
  • MPA $9.87
  • 52 Week High
  • IPHA $3.51
  • MPA $12.21
  • Technical
  • Relative Strength Index (RSI)
  • IPHA 53.30
  • MPA 39.61
  • Support Level
  • IPHA $1.81
  • MPA $10.38
  • Resistance Level
  • IPHA $2.00
  • MPA $10.72
  • Average True Range (ATR)
  • IPHA 0.14
  • MPA 0.16
  • MACD
  • IPHA 0.02
  • MPA -0.00
  • Stochastic Oscillator
  • IPHA 53.76
  • MPA 45.28

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

About MPA Blackrock MuniYield Pennsylvania Quality Fund

Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.

Share on Social Networks: